Name,Aptamer Target,Selection Method,Application,Sequence,Reference
N55,inflamed endothelial cells,stimulus-response cell-SELEX (SRC-SELEX),atherosclerosis plaque detection,5′-ATACCAGCTTATTCAATTCC                        CAAATTGCCACCACTTACAG                        CATGATAACATACTACATCTT                        TTCATCAAGATAGTAAGTGCAATCT-3′,Ji et al.                           24
GBI-10,tenascin-C,cell-SELEX,diagnosis and treatment delivery in several types of tumors,5′-GCCTGTTGTGAGCCTCCTCCC                        AGAGGGAAGACTTTAGGTTCGGTT                        CACGTCCCGCTTATTCTTGTCTCCC-3′,Daniels et al.                           32
SQ-2,ALPPL-2,cell-SELEX,identification of novel biomarkers for PDAC early diagnosis,5′-AUACCAGCUUAUUCAAUUGCC                        UGAAAAGCUAUCGCCCAAUU                        CGCAGUGAUAUCCUUUAAGAUAG                        UAAGUGCAAUCU-3′,Dua et al.                           52
NK2,H37Rv strain of MTB,cell-SELEX,tuberculosis treatment,5′-GCGGGATCCTATGACGCATTGACCCA                        CAACACACTACTGTCGCTCGGTTCGA                        ACTTCGTGCGACTGTTCCCTATAG                        TGAGTCGTATTAGAATTCCGC-3′,Chen et al.                           61
G-3,CCR5,cell-SELEX and HTS combination,HIV infection blockade,5′-UAAUACGACUCACUAUAGGGAGG                        ACGAUGCGGGCCUUCGUUUGUU                        UCGUCCAUCGGGCGAGUCGUCUG-3′,Zhou et al.                           72
P30-10-16,HA of influenza B virus,in vitro                        SELEX,influenza B virus infection blockade,5′-GGGAGAAUUCCGACCAGAAGAUUAUG                        CAGUUUCAUUAUAUCAUACACCAA                        CCUUUCCUCUCUCCUUCCUCUUC-3′,Gopinath et al.                           73
A07,TGFBR3,TECS-SELEX,inhibition of the interaction between TGFBR3 and TGF-β2                         in vitro,5′-GGGCCAGGCAGCGAGAGAUAAGCAGAA                        GAAGUAUGUGACCAUGCUCCAGAGA                        GCAACUUCACAUGCGUAGCCAAAC                        CGACCACACGCGUCCGAGA-3′,Ohuchi et al.                           77
MRP1Apt (3),MRP1,peptide-SELEX and cell-SELEX,tumor cell targeting for treatment delivery,5′-GGGAGAGGGAGAAUAGUCAACAAAUCGU                        UUGGGGCGACUUCUCCUUCCUUUCUCCC                        UUCUCCC-3′,Soldevilla et al.                           10
Apt02,ITGAV,Icell-SELEX,discovery of ligands for pharmaceutically challenging targets,5′-GGGAUCCGCAUCUAGAGUACUCCUCAG                        GCUUCAAUGCUUACGCAAUCCUGGGG                        GUCGAUGAACGUCUACUGAAGCUAUCA-3′,Takahashi et al.                           78
Sgc8,PTK7,cell-internalized SELEX,targeting ALL cells for drug delivery,5′-ATCTAACTGCTGCGCCGCCGGGAA                        AATACTGTACGGTTAGA-3′,Xiao et al.                           85
A1,HER2,cell-internalized SELEX,targeting HER2-positive breast cancer cells,5′-GGGAGGACGAUGCGGGACUGUACG                        GGGCUCUGUGCAGACGACUCGCCCGA                        CAGACGACTCGCTGAGGATC GAGA-3′,Thiel et al.                           82
J7,CD3ε,LIGS,expansion of T cell repertoire,5′-AAGGAGCAGCGTGGAGGATATCGGTAA                        GGGTCGGGGATGCTACAACTGTTTAAAC                        GACCCGTCCATTAGGGTGTGTCGTCGTGGT-3′,Zumrut et al.                           90
RNA 14-16,p68 oncogenic helicase,whole-organism                         in vivo                        SELEX,localization of metastasis in the liver,5′-GGGAGGACGATGCGGCAGUGCCCAA                        CCGGAACAACAACCACCGGCGGCU                        CCUGCU-3′,Mi et al.                           98
PB,activated endothelial cells,whole-organism                         in vivo                        SELEX,identification of bone metastases in prostate cancer,5′-CTCTATTGATGCCTGCGTGCGTGC                        TTGTAG-3′,Chen et al.                           102
GL21.T,Axl,cell-SELEX,treatment of Axl-dependent cancers,5′-AUGAUCAAUCGCCUCAAUUCGACAG                        GAGGCUCAC-3′,Cerchia et al.                           37
